Hydroxychloroquine shortened hospital stay and reduced intensive care unit admissions in hospitalized COVID-19 patients

Keywords: COVID-19, hydroxychloroquine, intensive care unit, mortality, inpatient duration

Abstract

Introduction: Effectiveness of hydroxychloroquine against SARS-CoV-2 has been highly controversial. In our research, we aimed to investigate the effects of hydroxychloroquine on disease outcomes in hospitalized patients with COVID-19.

Methodology: A total of 393 hospitalized patients with COVID-19 were retrospectively assigned to the standard of care therapy group (n = 180) or the standard of care plus hydroxychloroquine group (n = 213). The standard of care therapy comprised favipiravir, low molecular weight heparin, acetylsalicylic acid. Status of oxygenation at baseline and on the seventh day, laboratory tests at baseline and at discharge were recorded. Length of hospital stay, administration of anti-inflammatory treatment, admission to the intensive care unit and 28th day mortality were set as primary endpoints.

Results: There were no statistically significant differences between groups in terms of oxygen delivery route and mortality after seven days of treatment (p = 0.592). C-reactive protein levels of the standard of care plus hydroxychloroquine group were significantly lower than that of the standard of care group at discharge (p = 0.034). Patients in the standard of care plus hydroxychloroquine group had shorter hospital stay (p = 0.007). The standard of care plus hydroxychloroquine group was favored over standard of care group in terms of rate of intensive care unit admissions (21.7% vs. 10.8%; relative risk with 95% CI = 0.49 [0.31-0.80], p = 0.003).

Conclusions: Hydroxychloroquine in addition to standard of care was associated with less intensive care unit admissions, early discharge and greater C-reactive protein reduction. There was no difference in 28-day mortality.

Downloads

Download data is not yet available.

Author Biographies

Ahmet Omma, Department of Internal Medicine, Division of Rheumatology, Ankara City Hospital, Ankara, Turkey

Assoc Prof

Abdulsamet Erden, Department of Internal Medicine, Division of Rheumatology, Ankara City Hospital, Ankara, Turkey

Assoc Prof.

Meryem Aslan, Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey

M.D.

Hüseyin Çamlı, Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey

M.D.

Enes Seyda Şahiner, Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey

M.D.

Serdar Can Güven, Department of Internal Medicine, Division of Rheumatology, Ankara City Hospital, Ankara, Turkey

M.D.

Berkan Armağan, Department of Internal Medicine, Division of Rheumatology, Ankara City Hospital, Ankara, Turkey

M.D.

Selma Karaahmetoğlu, Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey

M.D.

Ihsan Ates, Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey

Assoc Prof.

Orhan Kucuksahin, Department of Internal Medicine, Division of Rheumatology, Ankara City Hospital, Ankara, Turkey

Assoc Prof.

Published
2022-01-31
How to Cite
1.
Omma A, Erden A, Apaydin H, Aslan M, Çamlı H, Şahiner ES, Güven SC, Armağan B, Karaahmetoğlu S, Ates I, Kucuksahin O (2022) Hydroxychloroquine shortened hospital stay and reduced intensive care unit admissions in hospitalized COVID-19 patients. J Infect Dev Ctries 16:25-31. doi: 10.3855/jidc.14933
Section
Coronavirus Pandemic

Most read articles by the same author(s)